Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Actavis (ACT) - Get Enact Holdings Inc Report: After an exclusive interview with Actavis CEO Brett Saunders, Cramer learned the company still believes research and development is the lifeblood of its industry. Saunders said Actavis will continue to discover and bring new drugs to market in areas where it has competitive advantages. He called Actavis one of the most productive companies when it comes to inventing new drug formulations.
When asked about Botox, a drug recently acquired when his company bought Allergan, Saunders noted that Botox is now used more for therapeutic purposes than aesthetic, including for migraines and overactive bladder. Actavis is also currently in Phase II studies for using Botox to treat depression.
Cramer told viewers there is so much more ahead for Actavis, especially after the Allergan acquisition.
Apple (AAPL) - Get Apple Inc. Report and General Motors (GM) - Get General Motors Company Report: If there was a March Madness for the stock market, Cramer said both of these Action Alerts PLUS holdings would be in his Midwest bracket. Apple reminds him of Kentucky and GM is a dead ringer for the Kansas Jayhawks, a chronically underestimated team. Shares of Apple trade at just 13.7 times earnings while GM trades at a scant 7.6 times earnings.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL and GM.